# Axitinib + Ipilimumab in Advanced Melanoma

> **NCT04996823** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 25 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Axitinib

## Key facts

- **NCT ID:** NCT04996823
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-04
- **Primary completion:** 2026-08-20
- **Final completion:** 2027-03-29
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-12-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04996823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04996823, "Axitinib + Ipilimumab in Advanced Melanoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04996823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*